PMID- 20568836
OWN - NLM
STAT- MEDLINE
DCOM- 20101004
LR  - 20211020
IS  - 1179-1950 (Electronic)
IS  - 0012-6667 (Linking)
VI  - 70
IP  - 10
DP  - 2010 Jul 9
TI  - Tinzaparin sodium: a review of its use in the prevention and treatment of deep 
      vein thrombosis and pulmonary embolism, and in the prevention of clotting in the 
      extracorporeal circuit during haemodialysis.
PG  - 1319-47
LID - 10.2165/11203710-000000000-00000 [doi]
AB  - Tinzaparin sodium (Innohep) is a low molecular weight heparin (LMWH) that is 
      effective in the prevention and treatment of deep vein thrombosis (DVT) and/or 
      pulmonary embolism (PE), and in maintaining the patency of haemodialysis circuits 
      in adult patients. In terms of preventing DVT and/or PE, therapy with 
      subcutaneous tinzaparin sodium was more effective than oral warfarin and 
      equivalent to subcutaneous enoxaparin sodium in patients undergoing orthopaedic 
      surgery, and did not significantly differ from that of subcutaneous 
      unfractionated heparin (UFH) in patients undergoing general surgery. In the 
      initial therapy of adult patients with DVT and/or PE, subcutaneous tinzaparin 
      sodium was at least as effective as intravenous UFH and did not significantly 
      differ from subcutaneous dalteparin sodium. Various other studies have 
      demonstrated that the long-term efficacy of subcutaneous tinzaparin sodium in the 
      treatment of patients with DVT and/or PE was sustained for a total period of up 
      to 12 months. Tinzaparin sodium was also demonstrated to be effective in 
      maintaining the patency of haemodialysis circuits in adult patients with 
      end-stage renal failure. In clinical studies, tinzaparin sodium was generally 
      well tolerated in the prevention and treatment of DVT and/or PE in adult 
      patients, including in elderly patients, and in patients undergoing 
      haemodialysis. As expected, bleeding complications were the most frequently 
      occurring adverse event. Thus, available data indicate that tinzaparin sodium is 
      a useful option in the prevention and treatment of DVT and/or PE, and in 
      maintaining the patency of haemodialysis circuits in adult patients.
FAU - Hoy, Sheridan M
AU  - Hoy SM
AD  - Adis, a Wolters Kluwer Business, Auckland, New Zealand. demail@adis.co.nz
FAU - Scott, Lesley J
AU  - Scott LJ
FAU - Plosker, Greg L
AU  - Plosker GL
LA  - eng
PT  - Journal Article
PT  - Review
PL  - New Zealand
TA  - Drugs
JT  - Drugs
JID - 7600076
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Heparin, Low-Molecular-Weight)
RN  - 7UQ7X4Y489 (Tinzaparin)
SB  - IM
MH  - Blood Coagulation/*drug effects
MH  - Clinical Trials as Topic
MH  - Fibrinolytic Agents/*administration & dosage/adverse 
      effects/pharmacokinetics/pharmacology
MH  - Heparin, Low-Molecular-Weight/*administration & dosage/adverse 
      effects/pharmacokinetics/pharmacology
MH  - Humans
MH  - Pulmonary Embolism/*drug therapy/*prevention & control
MH  - Renal Dialysis/*methods
MH  - Tinzaparin
MH  - Venous Thrombosis/*drug therapy/*prevention & control
RF  - 91
EDAT- 2010/06/24 06:00
MHDA- 2010/10/05 06:00
CRDT- 2010/06/24 06:00
PHST- 2010/06/24 06:00 [entrez]
PHST- 2010/06/24 06:00 [pubmed]
PHST- 2010/10/05 06:00 [medline]
AID - 7 [pii]
AID - 10.2165/11203710-000000000-00000 [doi]
PST - ppublish
SO  - Drugs. 2010 Jul 9;70(10):1319-47. doi: 10.2165/11203710-000000000-00000.